- Home
- OGI vs DSGN Comparison
OGI vs DSGN Comparison
Compare OGI & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGI
- DSGN
- Stock Information
- Founded
- OGI 2013
- DSGN 2017
- Country
- OGI Canada
- DSGN United States
- Employees
- OGI N/A
- DSGN N/A
- Industry
- OGI Biotechnology: Pharmaceutical Preparations
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- OGI Health Care
- DSGN Health Care
- Exchange
- OGI Nasdaq
- DSGN Nasdaq
- Market Cap
- OGI 231.9M
- DSGN 208.9M
- IPO Year
- OGI N/A
- DSGN 2021
- Fundamental
- Price
- OGI $1.65
- DSGN $6.45
- Analyst Decision
- OGI
- DSGN
- Analyst Count
- OGI 0
- DSGN 0
- Target Price
- OGI N/A
- DSGN N/A
- AVG Volume (30 Days)
- OGI 1.1M
- DSGN 184.3K
- Earning Date
- OGI 08-13-2025
- DSGN 11-06-2025
- Dividend Yield
- OGI N/A
- DSGN N/A
- EPS Growth
- OGI N/A
- DSGN N/A
- EPS
- OGI 0.05
- DSGN N/A
- Revenue
- OGI $164,107,753.00
- DSGN N/A
- Revenue This Year
- OGI $58.15
- DSGN N/A
- Revenue Next Year
- OGI $14.60
- DSGN N/A
- P/E Ratio
- OGI $38.85
- DSGN N/A
- Revenue Growth
- OGI 50.01
- DSGN N/A
- 52 Week Low
- OGI $0.85
- DSGN $2.60
- 52 Week High
- OGI $2.00
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- OGI 57.89
- DSGN 73.57
- Support Level
- OGI $1.56
- DSGN $4.92
- Resistance Level
- OGI $1.78
- DSGN $5.68
- Average True Range (ATR)
- OGI 0.09
- DSGN 0.42
- MACD
- OGI -0.00
- DSGN 0.08
- Stochastic Oscillator
- OGI 60.61
- DSGN 93.90
About OGI Organigram Holdings Inc.
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.